Board of Directors
Andrew is Mayo Clinic’s Director of Office of Translation to Practice, Director of HIV Research Lab and Director of Drug Discovery at Clinical and Translational Science (CCaTS). Dr. Badley is also currently a Professor of Medicine in the Division of Infectious Diseases at Mayo Clinic.
Andrew was born in Sydney, Nova Scotia, Canada. He earned his B.S. degree in 1985 and M.D. degree in 1990, both from Dalhousie University in Halifax, Nova Scotia.
After completing residency training in internal medicine at Mayo Clinic in Rochester, Minn., in 1994, Dr. Badley completed further training at Mayo Clinic as a clinician investigator trainee in the Division of Infectious Diseases in 1997.
During his training, Dr. Badley received the Dr. J. Geraci Award for Excellence in Infectious Diseases from Mayo Clinic in June 1997, as well as the Young Investigator Award from the Interscience Conference on Antimicrobial Agents and Chemotherapy and American Society for Microbiology (ICAAC/ASM) in September 1997.
Agustin recently served as Head of the Innovation and Advanced Analytics team and Head of Market Intelligence and Insights for the Global Oncology and Internal Medicine franchises at Shire.
Before Shire, Agustin co-founded and served as CEO/President of the cell immunotherapy start-up SQZ Biotech from 2013 to 2015. SQZ Biotech commercializes the CellSqueeze technology that was invented at MIT by Dr. Armon Sharei in the labs of biotech pioneer Professor Bob Langer and Professor Klavs Jensen. SQZ Biotech won the first prize in MassChallenge 2014 (out of 1,600+ start-ups) and it was selected as a FierceBiotech’s Fierce 15 company as one of the 15 most promising biotech startups in 2015. Its technology CellSqueeze was selected as one of the 10 world changing ideas by Scientific American in 2014. SQZ Biotech signed in 2015 a $500M deal with Roche to jointly develop cancer immunotherapies.
From 2010 until 2013, Agustin worked for Novartis Vaccines as part of the Global Leadership Program with international assignments in UK, Germany, Italy and US. He was the Global Value Chain Manager for the Novartis’ meningitis vaccines portfolio ($300m in annual sales).
Agustin started his career in P&G in 2005 as an R&D engineer where he led the development of a new product in Latin America. Both final product and marketing campaign obtained best results ever when tested among target consumers. Product was later introduced in Asia and Europe. Then, he completed his MS in Chemical Engineering at MIT in 2009. Agustin has a BS in Chemical Engineering from Universidad Simon Bolivar (Caracas, Venezuela).
Hutch has served as the founding CFO of several companies: Sonus Networks, Viaweb (acquired by Yahoo!), Winphoria Networks (acquired by Motorola), the Family Education Network (acquired by Pearson) and VideoServer (Nasdaq-EZEN). Hutch, a certified public accountant, was previously a Senior Manager at Deloitte & Touche and co-founder of the Boston office’s High Technology and Emerging Business Group. Hutchhas a Bachelor’s degree in Accounting from Bryant University.
Andrew Danielsen has been with Mayo Clinic Ventures since 2002 and is vice chair of licensing. He oversees the licensing, technology development, and business development functions of the office. Collectively, these groups work to identify, develop, and commercialize Mayo Clinic intellectual property. Prior to joining the office, Danielsen conducted research at Mayo Clinic where he worked to identify therapeutic targets in breast and ovarian cancer. He received a B.S. in biochemistry and molecular biology from the University of Wisconsin-Eau Claire, his M.S. degree in molecular biology from the Mayo Graduate School of Medicine, and is a registered Patent Agent.
Tim Barrows is a general partner at Matrix, where he has invested in technology start-ups for thirty years. In his role as a lead investor and board member, Tim has assisted entrepreneurs in ushering ventures from their earliest stages through to successful outcomes. More than 15 of the companies he helped establish and grow have gone onto successful acquisitions or IPOs.
Tim has advised and supported entrepreneurs across a range of technology sectors, including enterprise software, SMB-focused business services, communications and semiconductors. He has counseled entrepreneurs through multiple economic cycles and various technology booms, and has mentored many first-time CEOs.
Under Tim’s stewardship, Matrix Partners has delivered some of the highest performing funds of all time and expanded into international markets.
Prior to Matrix Partners, Tim worked in investment banking at Merrill Lynch White Weld, splitting his time between the technology group in corporate finance and the mergers and acquisitions group. He was also active in several seed stage investments.
While continuing to support entrepreneurs starting companies in the U.S., Tim leads the firm’s international efforts, which have included recruiting founding partners and establishing two new funds in Mumbai, India and Beijing, China.
Tim holds a BA in Political Economy from Williams College (magna cum laude, Phi Beta Kappa) and an MBA from Stanford Graduate School of Business.
David Goel co-founded Matrix Capital Management, a $2.2 billion long/short public equity fund with a 17-year track record. The fund holds a concentrated portfolio of high conviction, uniquely diligenced investment ideas, with a focus on technology, media/telecom, consumer, and service industries. The investment team operates with an ownership mindset, as the General Partner and related parties represent approximately 40% of capital. The team sources proprietary ideas internally and from its entrepreneur base, and builds its high conviction through an in-depth research process organized around a proprietary cloud-based platform. This diligence approach involves completing a high volume of primary diligence with industry participants as well as developing strong relationships with management teams to confirm and enhance the investment theses. The fund was recognized in Bloomberg Magazine’s “100 Top Performing Large Hedge Funds” as the second best performing hedge fund in 2013.
Prior to forming Matrix Capital Management in 1999, David was a Member at Tiger Management. Previously, he was an Associate at General Atlantic Partners and a Financial Analyst at Morgan Stanley, focusing on Technology Investment Banking. David is a Director of Univision Communications, Inc., the leading American Spanish broadcasting media company based in New York, NY. Mr. Goel is also a Director of Popular, Inc., a bank with operations in New York, Florida and Puerto Rico. He is a Trustee of Phillips Exeter Academy and a Trustee of the Museum of Fine Arts, Boston, MA. David received a Bachelor of Arts (Magna Cum Laude) from Harvard University and is a graduate of Phillips Exeter Academy.